Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday while also sharing more details on the internal culling of its R&D pipeline ...
Canaccord Genuity has adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) by reducing the stock's price target to $8.00 from the previous $9.00, while maintaining a Hold rating on the shares. The ...
Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "We ...
Five things you need to know, including another unicorn, Sage, Waltham apartments, Santander's CEO and Valentine's Day plans ...
Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company Biogen, after rejecting their $469 million buy-out proposal late last month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results